CADL, NGM

Candel Therapeutics, Inc. (CADL)

Price (as of October 28)

1.94USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

CRVS

Corvus Pharmaceuticals, Inc.

-0.18

FWBI

First Wave BioPharma, Inc.

-0.16

CRSP

CRISPR Therapeutics AG

-0.15

HCWB

HCW Biologics Inc.

-0.13

AGE

AgeX Therapeutics, Inc.

-0.11

CSBR

Champions Oncology, Inc.

-0.1

CINC

CinCor Pharma, Inc.

-0.09

ETTX

Entasis Therapeutics Holdings Inc.

-0.09

FNCH

Finch Therapeutics Group, Inc.

-0.09

ABIO

ARCA biopharma, Inc.

-0.09

Show more

Highest within Industry

Symbol Correlation

GLPG

Galapagos NV

0.19

ERAS

Erasca, Inc.

0.15

ERYP

ERYTECH Pharma S.A.

0.12

HOOK

HOOKIPA Pharma Inc.

0.11

CRMD

CorMedix Inc.

0.1

AGLE

Aeglea BioTherapeutics, Inc.

0.1

HARP

Harpoon Therapeutics, Inc.

0.1

GRNAW

GreenLight Biosciences Holdings

0.1

GRPH

Graphite Bio, Inc.

0.09

ALXO

ALX Oncology Holdings Inc.

0.09

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.